Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 9.06B P/E - EPS this Y -114.00% Ern Qtrly Grth -
Income 4.74B Forward P/E -10.83 EPS next Y -65.80% 50D Avg Chg 15.00%
Sales 158.3M PEG - EPS past 5Y - 200D Avg Chg 45.00%
Dividend N/A Price/Book 7.75 EPS next 5Y - 52W High Chg -2.00%
Recommedations 1.70 Quick Ratio 27.41 Shares Outstanding 739.52M 52W Low Chg 311.00%
Insider Own 29.09% ROA -15.03% Shares Float 363.16M Beta 1.26
Inst Own 74.86% ROE 127.72% Shares Shorted/Prior 33.57M/40.90M Price 11.81
Gross Margin -230.59% Profit Margin 2,991.76% Avg. Volume 4,793,029 Target Price 17.06
Oper. Margin -402.44% Earnings Date Nov 11 Volume 1,997,846 Change -1.01%
About Roivant Sciences Ltd.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd. News
10/29/24 Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
10/28/24 Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
09/18/24 Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
09/10/24 Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
09/10/24 Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
09/09/24 Roivant Provides Update on Graves’ Disease Development Program
09/04/24 The Federal Reserve should refresh its mandate: Former presidential candidate Vivek Ramaswamy
08/22/24 Shareholders In Roivant Sciences (NASDAQ:ROIV) Should Look Beyond Earnings For The Full Story
08/08/24 Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
07/25/24 Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
05/30/24 Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
05/16/24 Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
05/05/24 Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain
04/02/24 Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
03/26/24 Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
02/14/24 Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations
02/13/24 Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
02/10/24 Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares
01/30/24 Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
12/20/23 Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
ROIV Chatroom

User Image futurerobo34 Posted - 9 hours ago

$ROIV disappointed… stock should be well above $20.

User Image SirSloth Posted - 1 day ago

$ROIV 🤷🏻‍♂️

User Image TimingTimingTiming Posted - 1 day ago

$ROIV Will this go to the moon under Trump?

User Image DocPharm Posted - 3 days ago

$PFE $RHHBY $ROIV $ABUS Elections Rate reductions Earnings Calls Conferences, Oh, my

User Image DonCorleone77 Posted - 3 days ago

$ROIV $OGN Organon completes acquisition of Dermavant Organon (OGN) announced completion of its acquisition of Dermavant Sciences from Roivant (ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. VTAMA cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration for treatment of mild, moderate, and severe plaque psoriasis in adults with no safety label warnings or precautions and without restrictions on location and duration of use or body surface area. The FDA is reviewing a supplemental New Drug Application for VTAMA cream as a potential treatment for atopic dermatitis in adults and children two years of age and older, with Prescription Drug User Fee Act action expected in the fourth quarter of calendar year 2024.

User Image 30DeltaSpy Posted - 4 days ago

$ROIV im buying this when the market opens tomorrow

User Image DocPharm Posted - 6 days ago

$ABUS $ROIV always trade around a core position and build it out if you find a gem… Sell the highest shares when it spikes & if the opportunity presents, buy them back… In the end you end up with a lower avg & more shares ABUS , I started at 3.87 avg 4+ years ago. Now I’m sub 2.50 ☺️ with 8-10x the shares depending on the day

User Image countingguy2006 Posted - 6 days ago

$ABUS $ABUS $ROIV Adjust your positions accordingly. If you are holding these stocks for the long term, it's ok but take some profit on positions when it presents itself. Buy and hold long term without profit taking when considering inflation and the capital costs of money from letting it stagnate in reality is a loss and/or devaluing in your positions and brokerage accounts!

User Image T7Boeing Posted - 6 days ago

$ABUS $CRSP $EDIT $ROIV $SGMO — SANGFRAUDMO — No thanks. Zinc fingers are outdated dangerous tech. Little weaklings pumping a penny stock nearing bankruptcy amuse me

User Image brs555 Posted - 1 week ago

$ABUS There are a lot of well informed people here especially on the Arbutus/Roivant ST board. I have respectful positions in $SGMO $ABUS $ROIV. $ROIV owns 84% of Genevant a private company. $EDIT announced yesterday they are in collaboration with Genevant to develop novel gene editing therapeutics using the $CRSP platform. My question is WHY? Sangamo has a game changing editing system. $SGMO is valued at $330m. Crispr $4B. $ROIV should take a controlling stake in $SGMO. Fabry is Icing on the cake. Forget that deal with $EDIT. https://www.sangamo.com/science/technology-platforms/zinc-finger-platform/

User Image DocPharm Posted - 1 week ago

$MRNA almost time to build a position here… Below my target but still have a lot to address with $roiv & $abus Without delivery, there is no pipeline 👀👀

User Image SpaceCityKid Posted - 1 week ago

$ROIV Trying hard to turn up off the bottom of channel. Next tgt 12.32

User Image brs555 Posted - 1 week ago

@thebenchwarmers Matts repeatedly said that's not their wheelhouse. IE the $EDIT deal is. Small hits..singles doubles...That's why $ROIV doesn't go anywhere....HELL it doesn't even go anywhere when they hit a home run for over $5 Billion. I've said it before. Roivant is a holding company. Not a biotech. Not going anywhere unless the cash price for their shares increases... IE sold VTAMA recently...

User Image brs555 Posted - 1 week ago

$ROIV $ABUS Roivant $1M share trade after hours

User Image mbentinck Posted - 1 week ago

$IPA $ROIV $RXRX https://seekingalpha.com/article/4728318-roivant-sciences-good-value-but-near-term-catalysts-could-bring-volatility "What these partnerships and subsidiaries make very clear is that Techbio is hot in big pharma land and that more and more partnerships are being forged in recent years. Investing opportunities in Techbio land are plenty. In the more aggressive part of my portfolio, my personal favorite here is ImmunoPrecise Antibodies Ltd. (IPA), a company which has an EV/revenue multiple of only 1.37, has several partnerable assets in its subsidiary TALEM Therapeutics, and has an impressive AI-based engine called BioStrand that has only recently been commercialized.”

User Image insiderbuyingselling Posted - 1 week ago

$ROIV new insider selling: 100000 shares. http://insiderbuyingselling.com/?t=ROIV

User Image DENARIUS_CENTURION Posted - 1 week ago

$ROIV $IPA $RXRX

User Image Victor_Lustig Posted - 1 week ago

$IPA $RXRX $ROIV https://seekingalpha.com/article/4728318-roivant-sciences-good-value-but-near-term-catalysts-could-bring-volatility "In the more aggressive part of my portfolio, my personal favorite here is ImmunoPrecise Antibodies Ltd. (IPA), a company which has an EV/revenue multiple of only 1.37, has several partnerable assets in its subsidiary TALEM Therapeutics, and has an impressive AI-based engine called BioStrand that has only recently been commercialized."

User Image DocPharm Posted - 1 week ago

$ROIV ⏱️ ⏱️ ⏱️ $PFE $MRNA $ABUS Summary: Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant have bolstered Roivant's cash reserves. Key potential catalysts include Immunovant’s batoclimab in Phase 3 trials and namilumab in a Phase 2 trial, though drug candidate performance remains a critical risk factor. Litigation against Moderna and Pfizer, coupled with Techbio advancements, could drive future valuation.

User Image DocPharm Posted - 1 week ago

$ABUS $gsk But let’s not forget the pioneers $ABUS $ROIV $genevant If the damages of GSK could be so severe, I can’t imagine the ones already pending with the aforementioned

User Image Tparn Posted - 1 week ago

$ROIV …mid $11’s = total buy zone…

User Image DocPharm Posted - 1 week ago

$XBI can only suppress for so long…too much money flowing in Adding on dips $ROIV $PFE $ABUS $RHHBY

User Image UncleStock Posted - 1 week ago

$INBX $ICG $IH $ROIV suggested for Greenblatt - value screen: https://zpr.io/UTuPZph7JaaR

User Image invisio Posted - 2 weeks ago

@furzah @EdDwg @thebenchwarmers if and when this is proven right $ROIV could buy out $BRNS instead of acquiring $ABUS , which they already own and control.. advantage is they know the study results before any other interested party.. the chart of $BRNS looks like it's going the trash way with a current mcap of just $45m , maybe they do know that they are endangered to run out of money sooner or later and not being able to finance further studies without any solvent partner.. ROIV could fill that gap!

User Image RonIsWrong Posted - 2 weeks ago

$ROIV knocking on that $12 door, again.

User Image DocPharm Posted - 2 weeks ago

with vanguard being a big holder of $abus ; I’m sure the new BoD at $PFE is highlighting a big risk they haven’t addressed with their somewhat pal $ROIV just yet LNP; Marksman 18 Dec $abus /$roiv /$pfe

User Image CDMO Posted - 2 weeks ago

$ROIV looking good

User Image swizzlesticks Posted - 2 weeks ago

$ROIV Sad part China has lost $ 20 trillion in the largest asset in the world with there reality

User Image swizzlesticks Posted - 2 weeks ago

$ROIV GSK now in lawsuit with MRNA

User Image Joe_Mama Posted - 2 weeks ago

$ROIV In the channel. Can we break into the upper half

Analyst Ratings
Cantor Fitzgerald Overweight Sep 19, 24
HC Wainwright & Co. Buy Sep 19, 24
B of A Securities Neutral Sep 11, 24
HC Wainwright & Co. Buy Sep 11, 24
Cantor Fitzgerald Overweight Sep 9, 24
HC Wainwright & Co. Buy Aug 19, 24
Piper Sandler Overweight Jul 10, 24
Cantor Fitzgerald Overweight Jun 18, 24
HC Wainwright & Co. Buy May 31, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Venker Eric Chief Operating Offi.. Chief Operating Officer Oct 02 Sell 10.39 1,200,000 12,468,000 595,397 10/04/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Oct 02 Option 3.85 1,200,000 4,620,000 748,424 10/04/23
MANCHESTER KEITH S Director Director Sep 28 Sell 11.55 6,896,144 79,650,463 5,023,787 10/02/23
SVF Investments (UK) Ltd Director Director Sep 28 Sell 12.60 10,000,000 126,000,000 73,031,667 10/02/23
Gold Daniel Allen Director Director Sep 28 Sell 11.55 10,000,000 115,500,000 5,023,787 10/02/23
QVT Financial LP Director Director Sep 28 Sell 11.55 10,000,000 115,500,000 5,023,787 10/02/23
Venker Eric President & COO President & COO Sep 27 Sell 13.02 500,000 6,510,000 595,397 09/29/23
Venker Eric President & COO President & COO Sep 27 Option 3.85 500,000 1,925,000 1,095,397 09/29/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 08 Sell 12.19 106,430 1,297,382 611,813 09/12/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 08 Option 3.85 106,430 409,756 718,243 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 08 Sell 12.18 99,350 1,210,083 197,950 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 08 Option 6.48 99,350 643,788 297,300 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 05 Sell 12 1,724 20,688 197,950 09/07/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 05 Option 6.48 1,724 11,172 199,674 09/07/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 04 Sell 11.89 93,964 1,117,232 611,813 09/06/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 04 Option 3.85 93,964 361,761 617,739 09/06/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 14 Sell 11.89 59,811 711,153 627,918 08/16/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 14 Option 3.85 59,811 230,272 687,729 08/16/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 03 Sell 11.93 44,629 532,424 627,918 08/07/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 03 Option 3.85 44,629 171,822 672,547 08/07/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Aug 01 Sell 12 4,017 48,204 199,328 08/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Aug 01 Option 6.48 4,017 26,030 203,009 08/03/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 31 Sell 11.9 195,166 2,322,475 627,918 08/02/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 31 Option 3.85 195,166 751,389 644,315 08/02/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 25 Option 3.85 125,534 483,306 651,540 07/27/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 25 Sell 10.92 125,534 1,370,831 627,918 07/27/23
Venker Eric President & COO President & COO Jul 20 Sell 11.12 374,466 4,164,062 644,215 07/24/23
Venker Eric President & COO President & COO Jul 20 Option 3.85 374,466 1,441,694 677,296 07/24/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jul 14 Sell 12 635 7,620 82,128 07/18/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jul 14 Option 6.48 635 4,115 82,228 07/18/23
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Jun 22 Sell 9.9 13,000,000 128,700,000 12,884,307 06/26/23
VIKING GLOBAL PERFORMANCE LLC 10% Owner 10% Owner Jun 22 Sell 9.9 13,000,000 128,700,000 12,884,307 06/26/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jun 09 Sell 9.93 43,893 435,857 198,582 06/13/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jun 09 Option 5.12 43,893 224,732 242,475 06/13/23
Venker Eric President & COO President & COO Jun 07 Sell 9.88 299,585 2,959,900 660,097 06/09/23
Venker Eric President & COO President & COO Jun 07 Option 3.85 299,585 1,153,402 959,481 06/09/23
Venker Eric President & COO President & COO May 23 Option 3.85 415 1,598 676,183 05/25/23
Venker Eric President & COO President & COO May 23 Sell 9.85 415 4,088 675,768 05/25/23
Venker Eric President & COO President & COO May 09 Sell 9.23 238,724 2,203,423 675,768 05/11/23
Venker Eric President & COO President & COO May 09 Option 3.85 238,724 919,087 914,492 05/11/23
Venker Eric President & COO President & COO May 04 Sell 8.62 150,044 1,293,379 675,768 05/08/23
Venker Eric President & COO President & COO May 04 Option 3.85 150,044 577,669 736,974 05/08/23
Venker Eric President & COO President & COO May 01 Sell 8.43 288,989 2,436,177 675,768 05/03/23
Venker Eric President & COO President & COO May 01 Option 3.85 288,989 1,112,608 794,528 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer May 01 Sell 8.5 77,736 660,756 200,139 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer May 01 Option 3.85 77,736 299,284 215,656 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Apr 26 Sell 8.55 230,788 1,973,237 200,139 04/28/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Apr 26 Option 3.9 230,788 900,073 272,128 04/28/23
Venker Eric President & COO President & COO Apr 26 Sell 8.55 222,243 1,900,178 675,768 04/28/23
Venker Eric President & COO President & COO Apr 26 Option 3.85 222,243 855,636 751,591 04/28/23